ERBB2 and breast carcinoma: However, we recently reported that the relatively rare HER2L869R mutation increased HER2-mediated signaling and growth of MCF10A mammary epithelial cells; in addition, a breast cancer patient with this mutation showed an excellent response to neratinib [91].